Category: Focal Treatment & Laser Ablation

For years, men with low-risk prostate cancer had two options and nothing in between: remove or irradiate the whole gland, or leave it alone and watch. About half who chose watching later quit, and most of them had no evidence their cancer had changed at all. Focal laser ablation closes that gap, and it changes the calculation entirely. keep reading

No study has ever compared focal laser ablation and radiation head to head. The two fields even define failure differently, one by the need for retreatment and the other by a rising PSA. That makes a fair comparison harder than it looks, and makes understanding what each number actually measures essential before choosing. keep reading

Most prostate cancer treatments ask men to trade something away. Surgery risks incontinence in up to 30% of patients. Radiation carries a 27% cumulative risk of a secondary cancer. Focal laser ablation reports side effect rates under 1% while matching whole gland cancer control. The catch is smaller than most men expect, and worth knowing before deciding. keep reading

For years, focal therapy carried an unofficial label: promising, but unproven. A 2026 analysis of 3,477 men with localized prostate cancer changes that. Ten years after treatment, almost none had died of prostate cancer, and almost none saw it spread beyond the gland. The same cancer control as surgery, with far less damage along the way. keep reading

Nearly every man treated for low-risk prostate cancer survives it. That shifts the real question from whether treatment works to what life looks like once it is over. A five-year study followed 866 men and asked them, year after year, about leaking, bowel habits and sexual function. Focal therapy held up best across almost every measure. keep reading

By age 80, up to 90% of men have an enlarged prostate, and for many the first sign is a urinary symptom that will not go away. Standard procedures push the urethra open from within. A newer option, transperineal laser ablation, works from the outside instead, reducing prostate tissue so the passage reopens on its own over time. keep reading

For decades, a localized prostate cancer diagnosis came with two options: treat the whole gland and accept the side effects, or watch and wait. It was an all-or-nothing choice. Focal therapy changed the math. New 10-year international data shows cancer control comparable to radical prostatectomy, with far less risk to urinary and sexual function. keep reading

Not every prostate cancer patient wants to choose between surgery and surveillance. Transperineal Focal Laser Ablation offers a third path, and it requires far less specialized equipment than MRI-guided ablation does. That makes the procedure shorter, simpler, less costly, and considerably easier for patients to access. keep reading

For localized prostate cancer, the options can feel like two extremes: treat the whole gland and risk lasting side effects, or treat none of it and live with the worry of watching and waiting. Focal therapy sits in between. By destroying just the tumor and a small margin around it, it aims for cancer control close to radical treatment while preserving the quality of life that comes with treating none of the gland. keep reading

Why treat an entire prostate when the trouble usually starts in one spot? That question sits at the heart of focal therapy. For decades the answer was that doctors couldn't see or target the tumor precisely enough. Advances in multiparametric MRI, MRI-guided biopsy, and the index lesion concept finally changed that, opening a middle path between radical treatment and active surveillance. keep reading